Develops a micro‑dose formulation of ambrisentan, an endothelin receptor antagonist and pulmonary vasodilator designed to restore organ blood flow and oxygen delivery with potentially fewer side effects at lower doses. Targets high‑risk patients with severe COVID‑19 pneumonia, portal hypertension and other endothelin‑mediated vascular conditions; seeking co‑development partners.